Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment (Q74587806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

J O Christensen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

M Baumann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

B Clemmesen

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 May 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

559-564

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Early postmenopausal diminution of forearm and spinal bone mineral density: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Biochemical markers of bone turnover for the clinical investigation of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Noninvasive assessment of bone mineral and structure: state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Western blots of immune globulin preparations for intravenous use.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Longitudinal precision of dual-energy x-ray absorptiometry in a multicenter study. The Nafarelin/Bone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Premenopausal and postmenopausal changes in bone mineral density of the proximal femur measured by dual-energy x-ray absorptiometry

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Prevention of postmenopausal bone loss by tiludronate

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Biochemical markers of bone turnover. II: Diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

A critical review of bone mass and the risk of fractures in osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Total and regional body-composition changes in early postmenopausal women: age-related or menopause-related?

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS8756-3282%2898%2900044-1

7 January 2021

10.1016/S8756-3282(98)00044-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9600792%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference